Abstract
Abstract Viral genomics and bioinformatics is the linkage of viral genomic information with the viral and clinical parameters of patients, including therapy details and host genomics for the development of individualized patient management. In addition to variation between HBV isolated from different patients due to genotypes, naturally occurring mutations and quasispecies, new mutations are selected due to antiviral drug pressure. As viremic patients with antiviral resistant viruses continue to be treated with the initial antiviral agent, they will select further compensatory mutations. These mutations may also affect treatment with a second or third antiviral agent. Thus, the emergence of mutations in intricate patterns provides further support for the need for interactive databases due to the evolving complexity of the HBV genome. Since drug‐selected HBV mutants can also act as vaccine escape viruses with the potential to infect the HBV vaccinated population, close monitoring of these mutants represents a high priority public health strategy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
